Mylan Bertek Pharmaceuticals
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Mylan Bertek Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,751 sponsors by registered trial count).
Mylan Bertek Pharmaceuticals: 10 sponsored US clinical trials, none currently recruiting.
Mylan Bertek Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 8 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 2 trials.
Top-decile sponsor footprint
Mylan Bertek Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
10 total, page 1 of 1
Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension
NCT00142584
Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans
NCT00145210
A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo
NCT00158093
A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension
NCT00200434
A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension
NCT00200421
A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients
NCT00200499
Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension
NCT00145236
A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients
NCT00200473
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
NCT00200460
Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease
NCT00142545
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 8 |
Therapeutic Areas
How the Mylan Bertek Pharmaceuticals archive is shaped
10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).
Phase mix: 8 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: Hypertension (2 trials), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.